Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD.

ABSTRACT:

Background

As the prevalence of metabolic dysfunction-associated steatotic liver disease increases, it is imperative to have noninvasive alternatives to liver biopsy. Velacur offers a non-invasive, point-of-care ultrasound-based method for the assessment of liver stiffness and attenuation. The aim of this study was to perform a head-to-head comparison of liver stiffness and liver fat determined by Velacur and FibroScan using MRI-based measurements as the reference standard.

Methods

This prospective cross-sectional study included 164 adult participants with well-characterized metabolic dysfunction-associated steatotic liver disease. Patients underwent a research exam including Velacur, FibroScan and contemporaneous magnetic resonance elastography, and magnetic resonance imagi

SUBMITTER: Loomba R 

PROVIDER: S-EPMC10962894 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature